MX2020011562A - Agonistas del receptor de la hormona tiroidea y usos de los mismos. - Google Patents

Agonistas del receptor de la hormona tiroidea y usos de los mismos.

Info

Publication number
MX2020011562A
MX2020011562A MX2020011562A MX2020011562A MX2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A MX 2020011562 A MX2020011562 A MX 2020011562A
Authority
MX
Mexico
Prior art keywords
hormone receptor
thyroid hormone
receptor agonists
methods
compositions
Prior art date
Application number
MX2020011562A
Other languages
English (en)
Inventor
Gene Hung
Bohan Jin
Qing Dong
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of MX2020011562A publication Critical patent/MX2020011562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se describen métodos y composiciones para el tratamiento de afecciones, enfermedades o trastornos asociados con la actividad del receptor de la hormona tiroidea. Los métodos y composiciones descritos en la presente incluyen el uso de al menos un agonista del receptor de la hormona tiroidea.
MX2020011562A 2018-06-12 2019-05-28 Agonistas del receptor de la hormona tiroidea y usos de los mismos. MX2020011562A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684113P 2018-06-12 2018-06-12
US201862731364P 2018-09-14 2018-09-14
US201862767402P 2018-11-14 2018-11-14
PCT/US2019/034199 WO2019240938A1 (en) 2018-06-12 2019-05-28 Thyroid hormone receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2020011562A true MX2020011562A (es) 2021-02-02

Family

ID=68842670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011562A MX2020011562A (es) 2018-06-12 2019-05-28 Agonistas del receptor de la hormona tiroidea y usos de los mismos.

Country Status (10)

Country Link
US (1) US11964964B2 (es)
EP (1) EP3807267A4 (es)
JP (1) JP7181386B2 (es)
KR (1) KR102531771B1 (es)
CN (2) CN111801324B (es)
AU (1) AU2019287679B2 (es)
BR (1) BR112020022146A2 (es)
CA (1) CA3099752C (es)
MX (1) MX2020011562A (es)
WO (1) WO2019240938A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111317C (en) 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US11485729B2 (en) 2018-01-23 2022-11-01 Shenzhen Targetrx, Inc. Substituted pyridazinone compound
AU2019287679B2 (en) 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US11203587B2 (en) 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US20210355110A1 (en) * 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111592528A (zh) * 2019-02-20 2020-08-28 苏州泽璟生物制药股份有限公司 氘代的哒嗪酮及其衍生物和药物组合物
CN113474335A (zh) * 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
SG11202111552YA (en) * 2019-05-08 2021-11-29 Aligos Therapeutics Inc MODULATORS OF THR-ß AND METHODS OF USE THEREOF
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
CN112409340B (zh) * 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
JP2022549009A (ja) * 2019-09-24 2022-11-22 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 甲状腺ホルモンベータ受容体アゴニストとしての化合物及びその使用
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
US20230089582A1 (en) * 2019-11-26 2023-03-23 Kpc Pharmaceuticals, Inc 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CA3192169A1 (en) * 2020-09-17 2022-03-24 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
WO2022068915A1 (zh) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
MX2023004658A (es) 2020-10-23 2023-05-18 Madrigal Pharmaceuticals Inc Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea.
CN116723844A (zh) * 2020-11-06 2023-09-08 阿利戈斯治疗公司 作为甲状腺激素受体β (TR-β)激动剂的双环哒嗪酮
AU2021376281A1 (en) 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Pyridazinone derivatives as thyroid receptor agonists and uses thereof
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
KR20240018414A (ko) * 2021-03-04 2024-02-13 후캉 (상하이) 헬스 테크놀로지 씨오 엘티디 방향족 화합물, 그 제조 방법 및 적용
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
CN114409524A (zh) * 2021-12-31 2022-04-29 上海柏狮生物科技有限公司 一种2,6-二氯苯乙酸的制备方法
TW202342457A (zh) * 2022-02-07 2023-11-01 大陸商四川海思科製藥有限公司 一種嗒𠯤酮衍生物製備方法及其中間物
WO2023147752A1 (zh) * 2022-02-07 2023-08-10 四川海思科制药有限公司 作为甲状腺激素受体激动剂的多晶型物及其用途
WO2023154842A1 (en) * 2022-02-10 2023-08-17 Madrigal Pharmaceuticals, Inc. Thr beta analogs and uses thereof
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020786T2 (de) * 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2007009913A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CA3111317C (en) * 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US10682344B2 (en) * 2016-06-03 2020-06-16 Chemocentryx, Inc. Method of treating liver fibrosis
EP4112056A1 (en) 2016-10-18 2023-01-04 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
US11485729B2 (en) * 2018-01-23 2022-11-01 Shenzhen Targetrx, Inc. Substituted pyridazinone compound
AU2019287679B2 (en) 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
WO2019242766A1 (zh) 2018-06-22 2019-12-26 成都海创药业有限公司 氘代mgl-3196化合物及其用途
US20210355110A1 (en) 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
KR20200143711A (ko) 2020-12-24
CN111801324A (zh) 2020-10-20
EP3807267A1 (en) 2021-04-21
AU2019287679B2 (en) 2022-04-21
US11964964B2 (en) 2024-04-23
CA3099752C (en) 2023-12-19
KR102531771B1 (ko) 2023-05-11
US20210115022A1 (en) 2021-04-22
BR112020022146A2 (pt) 2021-01-26
CN111801324B (zh) 2021-10-22
JP2021531325A (ja) 2021-11-18
WO2019240938A1 (en) 2019-12-19
EP3807267A4 (en) 2022-03-16
CA3099752A1 (en) 2019-12-19
JP7181386B2 (ja) 2022-11-30
CN113683597A (zh) 2021-11-23
AU2019287679A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2020005583A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2019003021A (es) Combinacion de agonistas de fxr.
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
AU2014352875A8 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2017013879A (es) Composiciones que comprenden anakinra.